Market Overview

UPDATE: Stifel Nicolaus Raises PT on InterMune Awaiting Inflection Point

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

In a report published Thursday, Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on InterMune (NASDAQ: ITMN), and raised the price target from $17.00 to $18.00.

In the report, Stifel Nicolaus noted, “We believe 4Q13 now likely represents the long-awaited inflection point investors have been waiting to materialize in the model. However, we note the realization of that upside now increasingly looks like it will coincide with the disclosure of a competitive P3 data point from BI's nintedanib. And, while our recent review of nintedanib safety/tolerability data from ASCO would suggest Esbriet may have an advantage here, we note the introduction of another more-conveniently dosed agent of even equivalent/modest efficacy could limit visibility into a disease setting where a lack of definable progression makes it challenging for physicians to sequence therapy. However, we still find valuation and optionally around ASCEND data attractive here and remain Buy-rated.”

InterMune closed on Wednesday at $12.81.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: Stephen Willey Stifel NicolausAnalyst Color Price Target Analyst Ratings


Related Articles (ITMN)

View Comments and Join the Discussion!

Partner Center